Legend Biotech Corporation (LEGN) reported Q4 2025 adjusted earnings of $0.01 per share. No consensus estimate was available for comparison. Top-line revenue was $306.3M.
The biopharmaceutical company discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma.
Legend Biotech operates through its subsidiaries and focuses on advancing its CAR-T therapy platform for cancer treatment.
A detailed analysis of Legend Biotech Corporation’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post Legend Biotech Corporation (LEGN) Reports Q4 Earnings first appeared on Alphastreet.
